IgE-Based Therapeutic Combination Enhances Antitumor Response in Preclinical Models of Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) represents 3% of all cancer cases and 7% of all cancer deaths in the United States. Late diagnosis and inadequate response to standard chemotherapies contribute to an unfavorable prognosis and an overall 5-year survival rate of less than 10% in PDAC. Despite r...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Molecular cancer therapeutics 2021-12, Vol.20 (12), p.2457-2468
Hauptverfasser:	Markov, Spas Dimitrov, Caffrey, Thomas C, O'Connell, Kelly A, Grunkemeyer, James A, Shin, Simon, Hanson, Ryan, Patil, Prathamesh P, Shukla, Surendra K, Gonzalez, Daisy, Crawford, Ayrianne J, Vance, Krysten E, Huang, Ying, Eberle, Kirsten C, Radhakrishnan, Prakash, Grandgenett, Paul M, Singh, Pankaj K, Madiyalakan, Ragupathy, Daniels-Wells, Tracy R, Penichet, Manuel L, Nicodemus, Christopher F, Poole, Jill A, Jaffee, Elizabeth M, Hollingsworth, Michael A, Mehla, Kamiya
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma - drug therapy Animals Carcinoma, Pancreatic Ductal - drug therapy Humans Immunoglobulin E - pharmacology Immunoglobulin E - therapeutic use Mice
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!